BASKING RIDGE, N.J., April 2, 2007 (PRIME NEWSWIRE) -- Millennium Biotechnologies Group, Inc.(OTCBB:MBTG) today announced the findings of a 2nd clinical trial which concluded that Resurgex(r) sports nutritional formula significantly enhanced recovery, strength and body composition in Rutgers University Division 1 Football players as compared to a placebo group (a popular competitor sports formula). The results signal an important role for Resurgex in the sports fitness field.
The trial, conducted at Rutgers' New Brunswick, NJ campus and led by Assistant Professor of Exercise and Sports Studies Shawn M. Arent, PhD, CSCS, involved male, Division 1 varsity football players randomly assigned to receive either the NCAA compliant Resurgex sports formula or a placebo (a popular competitor sports formula) containing the same amount of calories throughout the study. The athletes were tested before and again at the end of training. Those receiving Resurgex showed significant increases in their peak power measured by Wingate testing, better muscle to fat weight gains and improved testosterone:cortisol ratio, reduction of IL6, creatine kinase and isoprostanes as compared with the control group. The practical application coming out of the study demonstrates the significant application of Resurgex as a post-workout recovery aid and will assist the athlete in maximizing training responses by helping to buffer the acute and chronic biochemical challenges to optimal recovery. A complete presentation of this study is to be given at the National Strength and Conditioning Coaches Association Conference in Atlanta, July 2007.
"Coupled with the significant results of our first clinical trial demonstrating the positive effects of Resurgex on performance and oxidative stress in Division 1 soccer players, this new clinical trial further confirms the critical role that Resurgex can play in the strength and recovery in the athlete," said Carl Germano, RD, CNS, CDN, senior vice president of product development and research for Millennium Biotechnologies. "With significant positive influences Resurgex had on recovery markers and its ability to reduce inflammatory and oxidative stress markers as well as compounds that can break down muscle, the results of this very important trial clearly show that Resurgex can have tremendous benefits when used as part of an athlete's normal training regimen. These findings provide a new opportunity for Millennium Biotechnologies to position Resurgex as an aid to help athletes increase their performance by improving recovery, strength and energy parameters."
About Millennium Biotechnologies, Inc.: Millennium Biotechnologies, Inc. is a research-based nutraceutical company and a pioneer in the emerging field of specialized nutritional supplements. The company's flagship products, RESURGEX(r), RESURGEX Plus(r), and RESURGEX Select(r), are designed to assist in reducing fatigue and oxidative stress, maintaining lean muscle and immune support in immunocompromised conditions.
Millennium Biotechnologies, Inc. is a wholly owned subsidiary of Millennium Biotechnologies Group, Inc., a publicly-traded company (OTCBB:MBTG). For more information about Millennium Biotechnologies, please contact Jerry Swon, Chief Executive Officer, at jswon@milbiotech.com or call (908) 604-2500. For more information about the Resurgex line of products visit www.resurgex.com.
This release includes certain forward-looking information that is based upon management's beliefs as well as on assumptions made by and data currently available to management. This information which has been, or in the future may be, included in reliance on the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, is subject to a number of risks and uncertainties, including but not limited to uncertainty as to market acceptance of Resurgex and Resurgex Plus and the factors identified in the Company's 10-KSB and other documents filed with the Securities and Exchange Commission. Actual results may differ materially form those anticipated in such forward-looking statements even if experience or future changes make it clear the any projected results expressed or implied therein may not be realized. The Company undertakes no obligation to update or revise any forward-looking statements to reflect subsequent events or circumstances.